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Abstract
Background: Recent developments in DNA microarray technology led to a variety of open and closed devices
and systems including high and low density microarrays for high-throughput screening applications as well as
microarrays of lower density for specific diagnostic purposes. Beside predefined microarrays for specific
applications manufacturers offer the production of custom-designed microarrays adapted to customers' wishes.
Array based assays demand complex procedures including several steps for sample preparation (RNA extraction,
amplification and sample labelling), hybridization and detection, thus leading to a high variability between several
approaches and resulting in the necessity of extensive standardization and normalization procedures.
Results: In the present work a custom designed human proteinase DNA microarray of lower density in
ArrayTube® format was established. This highly economic open platform only requires standard laboratory
equipment and allows the study of the molecular regulation of cell behaviour by proteinases. We established a
procedure for sample preparation and hybridization and verified the array based gene expression profile by
quantitative real-time PCR (QRT-PCR). Moreover, we compared the results with the well established Affymetrix
microarray. By application of standard labelling procedures with e.g. Klenow fragment exo-, single primer
amplification (SPA) or In Vitro Transcription (IVT) we noticed a loss of signal conservation for some genes. To
overcome this problem we developed a protocol in accordance with the SPA protocol, in which we included
target specific primers designed individually for each spotted oligomer. Here we present a complete array based
assay in which only the specific transcripts of interest are amplified in parallel and in a linear manner. The array
represents a proof of principle which can be adapted to other species as well.
Conclusion: As the designed protocol for amplifying mRNA starts from as little as 100 ng total RNA, it presents
an alternative method for detecting even low expressed genes by microarray experiments in a highly reproducible
and sensitive manner. Preservation of signal integrity is demonstrated out by QRT-PCR measurements. The little
amounts of total RNA necessary for the analyses make this method applicable for investigations with limited
material as in clinical samples from, for example, organ or tumour biopsies. Those are arguments in favour of the
high potential of our assay compared to established procedures for amplification within the field of diagnostic
expression profiling. Nevertheless, the screening character of microarray data must be mentioned, and
independent methods should verify the results.
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Background
Proteinases play an essential role in numerous biological
processes such as cell growth and differentiation, embry-
onic development, wound healing, antigen presentation
etc., but also for pathological events like inflammation,
coronary heart failure or cancer [1,2]. Above all, tumour
invasion and metastatic spread of tumours require the
activity of proteolytic enzymes [3]. Some proteinases have
been identified as prognostic markers for the overall sur-
vival of a patient, as well as an indicator for a metastasis-
free outcome post therapy. For instance there is evidence
for a positive correlation between the expression of
Matrixmetalloproteinases 2 and 9 (Gelatinases A and B)
and a poor prognosis in almost all kinds of cancer [4].
Urokinase (uPA), the urokinase receptor and the uPA
inhibitors PAI-1 and -2 are enhanced in several female
tumours [5-7]. Also, the Cathepsins B, L, K and S may play
an active role in cancer development [8] and inflamma-
tion diseases like rheumatoid arthritis [9]. Because of the
importance of proteolysis in vivo, it is of great interest to
better understand how the balance between active proteo-
lytic enzymes and their endogenous inhibitors is control-
led. Furthermore, it is also important to learn at which
level (expression, activation, compartimentalization) a
disturbed proteolysis is caused. The introduction of syn-
thetic inhibitors of proteinases as therapy concepts drew
high expectations for controlling or limiting the degrada-
tive potential of proteinases in e.g. cancer or rheumatoid
arthritis [9]. However, several aspects of such treatments
are still uncertain. Expression analysis using DNA micro-
array technology is one potent tool to study the involve-
ment of proteases in various normal and pathological
processes or to follow the expression during an inhibitor
treatment. However, it must be urgently stressed that such
analyses require confirmation by independent methods
such as e.g in vivo activity measurements of enzymes or at
least QRT- PCR measurements.
Recent developments in DNA microarray technology led
to a variety of open and closed devices and systems
including high and low density microarrays for high-
throughput screening applications as well as specific diag-
nostic purposes [10]. Beside predefined microarrays for
specific applications manufacturers offer the production
of custom designed microarrays adapted to customers'
wishes [11-15].
Array technology demands a complex procedure includ-
ing both the reproducible and robust array production
and the many steps in sample preparation (e.g. RNA
extraction, amplification and sample labelling), hybridi-
zation and detection which may frequently lead to a high
variability of the results between several and even equal
experiments. Therefore, standardization and normaliza-
tion procedures are very important and yet one of the
most time-consuming steps in the development of new
array based assays.
While analyzing RNA of clinical samples the amount of
material available often limits the examination. Direct
sample labelling via reverse transcription requires 20–100
μg total RNA [16] making this simple protocol inapplica-
ble for most routine diagnostic processes of clinical sam-
ples. Two main concepts offer solutions for this dilemma.
One possibility is to increase the labelling efficiency
(meaning a higher signal per molecule ratio). This has
been achieved using techniques like e.g. tyramide signal
amplification and/or amino-allyl labelling [17,18]. Other
protocols amplify the RNA necessary for labelling in a dif-
ferent manner. One basic protocol is the amplification of
aRNA (antisense RNA) by IVT (In Vitro Transcription), the
so called Eberwine protocol [19]. A variety of alternatives
to this costly and lengthy procedure have been developed:
SPA (Single Primer Amplification) [16], SMART technol-
ogy (Clontech)[20], Ribo-SPIA™ RNA amplification
(NuGEN) [21], amplification using terminal continua-
tion (TC RNA amplification) [22] etc. Numerous research-
ers investigated the conservation of differential expression
and reproducibility by comparison of different amplifica-
tion techniques, standardization and normalization of
array results [23-28], respectively.
The main challenge is to maintain the differences of
expression levels between different RNA species during
the labelling procedure in a reproducible manner. We
work with custom designed microarrays of low density in
the ArrayTube® format. This offers a cost effective platform
and requires only standard laboratory equipment and an
array tube reader (atr01). By application of standard label-
ling procedures (e.g. Klenow fragment exo-, single primer
amplification or IVT) we noticed a loss of some gene sig-
nals. In order to overcome this problem we developed a
modified SPA protocol. We included target specific prim-
ers designed individually for each spotted target oligomer.
Here we present the results by amplifying, labelling and
hybridizing specific transcripts of interest.
Results and discussion
Comparison of different labelling methods
Labelling in the course of reverse transcription of as much
as 5 μg total RNA resulted in non detectable or only very
poorly detectable hybridization signals (results not
shown). This was expected and corresponds to descrip-
tions in literature and to protocols recommending 25–
100 μg total RNA for direct reverse transcription labelling
reactions [16]. Therefore, we prepared samples according
to the alternative and modified protocols, respectively.
Figure 1 shows an example for transcribing and labelling
of total RNA extracted from HEK (human embryonic kid-BMC Genomics 2006, 7:144 http://www.biomedcentral.com/1471-2164/7/144
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ney) 293 (ACC # 305) cells according to three different
methods: A) Labelling of reverse transcribed cDNA in the
course of the reaction with Klenow fragment, B) Labelling
with Klenow fragment after amplification of total RNA
according to the Eberwine protocol [19] and C) synthesis
of double stranded cDNA starting from total RNA and
labelling in the course of linear amplification using a so-
called SPA-primer. Method A) yields labelled products of
sense- and antisense-direction, protocol B) and C) result
only in antisense stranded products being complementary
to the immobilized oligonucleotides on the array. The
overall hybridization patterns generated by the three dif-
ferent methods seem similar but are not identical. The sig-
nal intensity was stronger and the differentiation was in
the case of method C) more pronounced compared to
methods A) and B), despite the relatively small amount of
initial total RNA in this experiment. The question was
whether the improvement achieved by the SPA method
was subject to a better signal sensitivity, to a better signal
specificity or to both. In order to further study the differ-
ences in the expression profiles, we chose three cell lines
with different expression profiles – namely human fibrob-
lasts, DLD-1 and 97TM1 (two established cancer cell lines
derived from colon adenocarcinoma, ACC # 278 and
non-small cell lung cancer, resp., ACC # 388) – to prepare
hybridization samples in two different manners: with Kle-
now fragment exo- and by preparation of double stranded
DNA and labelling in the course of linear amplification
using SPA primer both starting from initially reverse tran-
scribed total RNA.
PCR experiments
In order to exclude false positive results on the array we
reverse transcribed the RNA of the three cell lines into
cDNA, which was then used as a template for PCR. A tem-
plate free control and a positive control were carried along
each PCR reaction. A negative result (no signal on the
array) should be confirmed by the absence of any PCR
product of the expected size (exclusion of contamination
by genomic DNA). However, as can be seen in Fig. 2, the
PCR results did not completely correspond to the array
data. The array showed weak but significant signals for
PAI-2 but we did not receive any PCR product for DLD-1
and 97TM1. And the signals for Matriptase were nearly
equal in all three cell lines, although human fibroblasts
did not show a PCR product. These unexpected results
required an explanation. First, we increased the stringency
of the washing procedure of the array in order to mini-
mize cross hybridization reactions, but we were unable to
change the arrangement and intensity of the hybridiza-
tion signals due to this. Furthermore, we excluded the pos-
sibility of false positive hybridization signals by initially
testing all spotted oligos of functionality by hybridization
with biotinylated PCR products generated with specific
primers from a corresponding plasmid cDNA (results not
shown). We did not observe any cross hybridization with
the cDNAs generated from plasmids.
Another possibility to explain the results was that they
were based by the labelling procedure itself. Therefore, we
decided – in contrast to the overall amplification with SPA
primer – to try a specific linear amplification as described
in the methods section where instead of the SPA primer
specific primers for every target were used. Additionally,
we incorporated biotinylated dUTP in the linear amplifi-
cation reaction using the primer mixture and thus, dimin-
ished the number of steps required for sample labelling
compared to original SPA protocol.
Labelling und Amplification of RNA from HEK293 Figure 1
Labelling und Amplification of RNA from HEK293. (A) Labelling of initially reverse transcribed c-DNA with Klenow 
fragment exo- (10 μg total RNA), (B) Amplification of total RNA according the Eberwine protocol [19], Labelling of 2 μg anti-
sense RNA with Klenow fragment exo-, (C) Labelling via SPA (0.25 μg total RNA).
A) B) C)BMC Genomics 2006, 7:144 http://www.biomedcentral.com/1471-2164/7/144
Page 4 of 14
(page number not for citation purposes)
For orientation, initially six oligonucleotides specific for 3
targets (Matriptase and the PAI-1 and 2) were tested
together. These experiments resulted in highly specific
hybridization signals matching exactly the expected tar-
gets (Fig. 3), however, revealed a strong dependence on
the primer concentration.
Optimization of the labelling protocol with specific 
primers
We investigated the influence of amplification tempera-
ture, primer concentration, reaction volume and ds-cDNA
concentration in order to further improve the labelling
protocol in the course of linear amplification with specific
oligonucleotides. As one example, Fig. 3 shows the signal
intensity and hybridization pattern at different primer
concentrations at an annealing temperature of 62°C. For
further investigations we have chosen a primer concentra-
tion of 60 nM each (final). It was applied in all assay
investigations to prevent cross reactions and thus, false
positive signals. In addition, that primer concentration
was the lowest one yielding detectable hybridization sig-
nals of all expected signals. The assay was well functioning
for that little primer set. This was in accordance with
descriptions of a similar procedure to amplify genomic
DNA with 39 oligos in a linear manner[14].
Experiments with an increased number of specific primers
Consequently, the behavior of the system was investigated
with a stepwise increasing number of specific primers.
Because of the complex reaction mixture cross hybridiza-
tion reactions may be expected which had to be ruled out.
The experiments were carried out with ds-cDNA from
human fibroblasts. In each experiment 100 ng total RNA
Comparison of PCR vs. hybridization pattern on the arrays Figure 2
Comparison of PCR vs. hybridization pattern on the arrays. A. Electrophoresis of PCR products. Initially reverse tran-
scribed c-DNA of human fibroblasts, DLD-1 and 97TM1 was used as template for PCR with specific primers for Matriptase, 
PAI-1 and PAI-2. Positive controls: plasmid-cDNAs of the three targets, negative controls were template free. Product sizes: 
matriptase 470 bp, PAI-1 687 bp, PAI-2 710 bp. B. Array analysis. Sample preparation was performed according to the protocol 
for overall linear amplification with the SPA primer and simultaneous labelling (see Methods part).
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were used. In a first series of experiments thirty two prim-
ers for 16 target genes were used and divided into 4
groups.
-Group 1: Matriptase, PAI-1 and 2 (the initial test mix)
-Group 2: MMP1, 3, 7, 13 and GAPDH
-Group 3: MMP2, 9, 16, β-actin
-Group 4: Cathepsins K and S, TIMP3, TIMP4
The single primer groups were used in amplification reac-
tions. The hybridization patterns were compared with the
results of PCR to omit false positive signals. Hybridization
signals were confirmed by positive results of the respective
PCR measurements. False positive signals were not
detected. In the following and final experiment all availa-
ble specific primers were combined and used for an
amplification reaction. We compared the hybridization
pattern of the three cell lines human fibroblasts, DLD-1,
97TM1, respectively, already chosen for the first experi-
ments (see above). We noticed a remarkably improved
specificity of the hybridization pattern compared to the
traditional labelling protocols. The results were in accord-
ance to the results of qualitative PCR experiments – the
number of hybridization signals essentially corresponded
with the number of positive signals in qualitative PCR.
Validation of results with real time measurements
The expression of selected genes was determined using
QRT- PCR in order to confirm the results of the array
experiments by an independent method. We have chosen
PAI-1, matriptase and TIMP3 because these target genes
showed differences in the development of hybridization
signals. Figure 4 shows the expression levels of these 3
genes in 6 different samples, normalized to the ß-actin
level: 97TM1, DLD-1, an established human fibroblast
line, primary synovial fibroblasts treated for 24 h with
either TGFβ or IL-6, respectively, or not treated. The nor-
malized signals obtained by QRT- PCR were compared
with those of the array experiments. A good overall corre-
spondence was found of the results achieved by the two
independent methods.
Dependence of signal development on primer concentration Figure 3
Dependence of signal development on primer concentration. ds-cDNA was generated from 0.6 μg total RNA of 
DLD-1 at 62°C by linear amplification using the primer mix for Matriptase, PAI-1 and PAI-2. Different primer concentrations 
are indicated. Hybridization to the Array tubes® in accordance to the protocol described in the Methods part.
1μM primer 100 nM primer 60 nM primer
30 nM primer 10 nM primerBMC Genomics 2006, 7:144 http://www.biomedcentral.com/1471-2164/7/144
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However, the graphic points to the qualitative screening
character of array experiments, too. We found a good but
did not find an absolute conformity between the signals
obtained by the different methods. Figure 5 points out
one reason for that finding. We calculated a lower limit for
the detection on the array of 0.1 fg of PAI-1, Matriptase
and TIMP3 cDNA, resp., in the sample (verified by QRT-
PCR). We consider this limit also as valid for all other tar-
get sequences. The linear range of signal development on
the array is limited and was found to be between 1 and
150 fg specific cDNA in the sample. Above this concentra-
tion, a further increase in signal intensity can not be
reached. The dynamic range of array analyses like this is
always limited and does never reach that of QRT-PCR. The
spotting of our arrays can only be minimally changed in
order to achieve a broader dynamic range due to technical
reasons. The detection method (pattern specific precipita-
tion of HRP product and measurement of transmission) is
a limiting factor for the dynamic range. However, the
enzymatic reaction on the array surface which proceeds in
a non linear manner and enhances the hybridization sig-
nal allows a very sensitive detection of the signal intensity
at every time point during the process of development
(see Fig. 6B). This means, the development of rare signals
may be seen when high concentrated targets are already in
the saturation range. As a consequence of that, the
amount of cDNA resulting from the reverse transcription
which is used for the specific linear amplification may be
Comparison of template specific hybridization pattern with QRT- PCR data Figure 4
Comparison of template specific hybridization pattern with QRT- PCR data. Signal intensities for matriptase, TIMP3 
and PAI-1 were normalized to the ß-actin signal. Upper part: array data; lower part: QRT- PCR data. Cell lines: 97TM1, DLD-
1, huFi (established line of human fibroblasts), primary synovial human fibroblasts either treated with IL-6 (huFiIL6) and TGFβ 
(huFiTGFß), respectively, for 24 h in FCS free medium, or non treated (huFiKo). Samples for the array experiments were 
labelled according to the linear amplification protocol with target specific primers. Amplifications in real time experiments 
were performed with gene specific primers (primer sequences: matriptase left primer: 5'-gat cct gca aaa ggg tga ga-3', right 
primer: 5'-cac ttt gga ggc tga gga ag-3'; TIMP3 left primer: 5'-ctt ctg caa ctc cga cat cg-3', right primer 5'-gta gtg ttt gga ctg gta gc-
3'; PAI-1 left primer: 5'-gat cga ggt gaa cga gag t-3', right primer: 5'-cac agt gga ctc tga gat g-3').BMC Genomics 2006, 7:144 http://www.biomedcentral.com/1471-2164/7/144
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enhanced by a factor of 2 or 3 or may be diluted tenfold,
respectively, in order to achieve reliable data. We are gen-
erally using about 100 ng of cDNA for that purpose,
knowing that not all transcription products are complete.
Signals of low expressed or incompletely transcribed
genes would be lost if only one concentration of cDNA is
used. This underlines again the screening character of the
array methodology which is further supported by results
presented in Fig. 6A. We generated synthetic polyA-RNA
from sequences of spike-in controls by in vitro transcrip-
tion. These different RNA preparations served as control
for sample labelling procedures, hybridization and detec-
tion. The absolute intensity of hybridization signals was
related to the amount of RNA spiked in. Even in this case,
we found a region of linear dependence, followed by sig-
nal saturation.
Array analyses are extremely dependent on a high repro-
ducibility. Most problems to be solved by an array analy-
sis are based on the direct comparison of a normal sample
with samples in which different expression is expected.
Therefore, competitive hybridization where two different
samples are labelled with e.g. Cy3 and Cy5, respectively,
and afterwards mixed and hybridized again one and the
same array is the mostly used technique in array based
expression profiling. In our experiences the modification
of only one part of the assay – e.g. just the polymerase
used for amplification – or of the protocol, results in non-
or hardly comparable array results. Not only the kind of
labelling but also the conditions of the labelling protocol
are very decisive for comparable and successful array
experiments.
The protocol of probe preparation presented in this man-
uscript is part of a complete evaluated and optimized
assay and results in a very specific signal development and
a high sensitivity of detection. Figure 7 refer to that fact by
direct comparing of the hybridization patterns of samples
generated from total RNA of DLD-1 cells by the different
labelling procedures. The linear amplification procedure
described here in combination with a signal enhancement
after hybridization by an enzymatic precipitation reaction
at the surface of the array produces a very specific signal
beside the remarkably small amount of RNA required.
Changes in gene expression of different proteinase RNAs
are well detectable, although the validation by independ-
ent procedures is absolutely required. The procedure is
cost and time effective. The high specifity of signal devel-
opment does not require an additional RNA purification.
Hybridization in array tubes takes not more than 3 hours;
it includes a control of signal development by bioti-
nylated markers, and spike-in controls. The in-time regis-
tration of signal development makes it possible to analyze
the array at a moment which is optimal for any selected
target. This option is of importance in cases where some
signals are quickly saturated at an early moment of meas-
urement.
Comparative hybridization experiments – Affymetrix 
whole genome chip Hu133 plus 2.0 versus tube array
To elucidate the quality of the new protocol we performed
comparative hybridization experiments with our assay
and with the well-established Affymetrix whole genome
chip Hu133. However, only 44 of the 49 targets present
on the tube array were also present on the Affymetrix chip.
We have chosen a stimulated and a non-stimulated sam-
ple (the established colon carcinoma cell line Coga-1 [29]
with and without Interleukin-6) to detect differences in
the expression profiles and to compare the results
achieved using the two different analytic systems. We were
aware of the difficulties to compare two absolutely differ-
ent systems concerning both the probe labelling protocol
and the detection method: affymetrix chip results in abso-
lute fluorescence values; array tube system applies a non
linear enzymatic precipitation reaction (and thus a signal
enhancement) to detect hybridization signals. The conse-
quence is a much higher dynamic range for the affymetrix
chip than the array tube may achieve. Nevertheless, the
gene expression profile should be the same applying the
different array systems, subject to the condition of high
quality of analyses.
Only one gene (MMP-1) was significantly down regulated
and that was found with both systems and was addition-
ally confirmed by quantitative RT-PCR (Figure 8).
With one exception, all expressed genes detected with the
Affymetrix chip (cut off: fluorescence value of 300, detec-
tion p-value < 0.065) were also found with the array tube,
only MMP-14 which showed very high fluorescence val-
Relative hybridization signal intensity on the array vs. the  absolute gene expression level Figure 5
Relative hybridization signal intensity on the array vs. 
the absolute gene expression level. The absolute 
amounts of TIMP3 cDNA and PAI-1 cDNA were determined 
by QRT- PCR measurements. These values are presented 
versus the relative hybridization signals on the array.
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ues on the Affymetrix chip was not detectable at the array
tube. However, the quantitative RT-PCR measurement
confirmed the result of the array tube (no expression of
MMP-14).
On the other hand, some hybridization signals which
were present at the array tubes were absent on the Affyme-
trix system (32 hits on the tube array vs. 21 on the Affyme-
trix system). In order to explain the differences we
checked five of the positive array hits with PCR and quan-
titative RT-PCR, respectively. Table 1 summarizes the
results for the non-stimulated cell line. The expression lev-
els of all genes listed in Table 1 were close to the detection
limit of quantitative RT-PCR or were detected as only faint
bands at the agarose gel, respectively.
Furthermore, we tried to correlate the hybridization signal
strength of genes with the absolute amount of RNA deter-
mined by quantitative RT-PCR. This result is illustrated in
Table 2 for five genes. The expression level of ST14 is one
order of magnitudes higher than that of MMP-1 as deter-
mined by RT-PCR, however, the relative fluorescence val-
ues obtained using the Affymetrix chip gave a 6-fold
higher value for MMP-1. A similar phenomenon was also
found using the array tube: whereas PAI-I was found to be
20 times less expressed as Cathepsin K, the tube array indi-
Hybridization signal intensity on the array obtained with different amounts of synthetic polyA-RNA spiked in Figure 6
Hybridization signal intensity on the array obtained with different amounts of synthetic polyA-RNA spiked in. 
Synthetic polyA-RNA species were generated using sequences of bacteriophage λ. An oligo (A)30 sequence at each 3'end was 
incorporated in the course of a PCR reaction. Templates for in vitro transcription with T7 RNA polymerase were engineered 
by cloning in a vector containing a T7 promotor and digesting with HIND III. The transcripts were purified with Oligotex 
mRNA Minikit (Qiagen, Hilden, Germany) to get pure polyA-transcripts. A) Different amounts of three synthetic polyA-tran-
scripts (B: light blue; H: margenta; J: black) were spiked in as exogenous controls for labelling, hybridization and detection. The 
hybridization signals determined after 10 min incubation with the HRP substrate are presented versus the amounts of controls 
spiked in. B) Data analysis at 2.5, 5 and 10 min, respectively, after incubation with the HRP substrate, shown for three different 
synthetic RNA concentrations (black: 3.2E-9 nmol of sequence J, light blue: 6.48E-9 nmol of sequence B, margenta: 1.14E-8 
nmol of sequence H). This way, the dynamic range of array analysis can be expanded to some extent.
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A direct comparison of the hybridization pattern of samples generated from total RNA of DLD-1 by the different labelling pro- cedures Figure 7
A direct comparison of the hybridization pattern of samples generated from total RNA of DLD-1 by the differ-
ent labelling procedures. (A) Labelling of 20 μg total RNA in the course of reverse transcription (biotinylated Oligo-dT), 
hybridization for 18 h at 45°C, 1 ng polyA-spike in controls were added. (B) 5 μg total RNA were reverse transcribed and the 
resulting cDNA was labelled by Klenow fragment exo-. (C) Labelling of ds-cDNA generated from 500 ng total RNA in the 
course of overall linear amplification with the SPA-primer. (D) Labelling of ds-cDNA generated from 100 ng total RNA and 10 
pg polyA-spike in controls in the course of linear amplification with the complete set of specific primers according to the pro-
tocol described in the Methods part.
(A)
(C)
(B)
(D)BMC Genomics 2006, 7:144 http://www.biomedcentral.com/1471-2164/7/144
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cated only a 2-fold higher expression of Cathepsin K than
of PAI-I. These findings again point to the screening char-
acter of array experiments.
However, the main application of array analyses is the
direct comparison of two samples as stimulated vs. non-
stimulated cells or normal vs. tumor tissue etc. For this
purpose, we found a good correlation of the expression
profiles determined with the two microarray systems/
probe preparation protocols, respectively, and the quanti-
tative RT-PCR results.
Conclusion
We designed a protocol for amplifying mRNA in a linear
mode from as little as 100 ng total RNA. The protocol
offers a simple method for detecting even low expressed
genes by microarray experiments in a reproducible and
sensitive manner. The central point of the method is the
linear ssDNA amplification step with concomitant label-
ling. Preservation of signal integrity and the little amounts
of total RNA necessary for this labelling protocol make
that method applicable for investigations with limited
amounts of material like clinical samples from biopsies or
tumours.
Methods
DNA microarray design and preparation
For the manufacturing of the arrays, 3'-aminomodified
oligonucleotides were purchased from Metabion (Martin-
sried, Germany). Oligonucleotides were used at a final
concentration of 10 μM in Spotting Buffer 1 (CLONDIAG
chip technologies GmbH, Jena, Germany) and spotted
using a Microgrid II spotting machine (Genomic Solu-
tions Ltd., UK) following the procedure supplied by the
manufacturer. Every probe was spotted redundantly two
times on the array. After production, arrays were inserted
into ArrayTube™ reaction vials.
Probe sequences were derived from published sequences
using the Array Design software package by Clondiag
Chip Technologies (Jena, Germany). In the additional
files 1, 2, 3 tables show target genes, sources of the
sequence data, as well as probe sequences and array lay-
out. Consensus regions in the alignments of all available
sequences of each target were chosen for the probe design.
The resulting sequences were selected to be specific for the
target and to have similar length, GC content and melting
temperatures in order to yield comparable signal intensi-
ties. The final probe sequences were again blasted against
the database [30] to exclude false-positive reactions due to
possible cross-reactivities or false-negative reactions due
to sequence variations.
The site directed oligonucleotide set for the linear ampli-
fication procedure consisted of 94 oligonucleotides. It was
designed according to the initial alignments for the probe
design as described above. For each target, a consensus
region was identified which was situated 5 to 50 bp
upstream of the probe binding site (see additional files).
Sequences with similar physicochemical parameters were
chosen from these regions and used for primer design.
The final primer sequences were blasted against the data-
Table 1: Hybridization signal strength of five genes found to be expressed using the array tube but not using the Affymetrix chip, 
respectively, compared with the results of quantitative PCR experiments (non-stimulated Coga cells). Array tube: relative 
transmission values, normalized overall. Affymetrix chip: relative fluorescence value, normalized overall
Gene Affymetrix chip Array tube PCR Quantitative RT-PCR
PAI-1 not present 0,53 4,34*10-7 ng
MMP7 not present 0,52 1,02*10-6 ng
MMP8 not present 0,47 positive
CST5 not present 0,89 positive
CTSK 273,8+) 0,43 8,13*10-6 ng
+) this value is below the cut off of 300.
Change of the expression levels of 4 genes in Coga cells after  stimulation with IL-6 analysed by three different methods Figure 8
Change of the expression levels of 4 genes in Coga 
cells after stimulation with IL-6 analysed by three dif-
ferent methods. Four expressed genes as determined on 
the Affymetrix chip, the array tube and by quantitative RT-
PCR were considered. The ratio values (non stimulated vs. 
IL-6 stimulated Coga cells) are indicated. (The ratio Coga/
Coga + IL-6 results in high values for down regulated genes 
after treatment with IL-6).
0
1
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8
Real time PCR affymetrix array tube(overall
normalization)
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base [30] avoiding possible cross-reactivities as well as
sequence variations. Primer sequences are also listed in
additional files (additional file 4). Oligonucleotides were
purchased from Invitrogen (UK). They were used as a
stock solution mixture with concentrations of 1 μM for
every individual primer.
The development of the Affymetrix microarray was per-
formed in an independent routine lab according to the
manufacturers recommendations. 5 μg purified RNA was
used as starting material for this purpose.
RNA preparation
Total RNA from cells and tissues was isolated with TRI-
ZOL® Reagent (Invitrogen, UK) according to the suppliers'
instruction. RNA was re-dissolved in RNase-free water.
The quality of the isolated RNA was controlled using non
denaturing 1.25% agarose gel electrophoresis and the
determination of the A260/A280 ratio (GeneQuant II, Phar-
macia Biotech). Only samples exhibiting no RNA degra-
dation and showing an A260/A280 ratio equal or above 1.8
were used for further applications. Preparations were
stored at -80°C.
Labelling by reverse transcription of total RNA
For direct labelling of cDNA via reverse transcription 10
μg of total RNA was mixed with 1.5 μl oligo-dT15-primer
(0.5 μg/μl, Promega, Mannheim, Germany) and sterile
water (final volume 14, 6 μl), denatured for 15 minutes at
65°C, then chilled on ice for 5 minutes. After a short cen-
trifugation step a mastermix consisting of 6 μl 5× First
Strand Buffer (Invitrogen), 2 μl 0.1 M DTT (Invitrogen),
0.7 μl RNaseOUT (Invitrogen, 40 U/μl), 2.5 μl 5 mM
dNTPs (dATP, dCTP, dGTP, Fermentas), 1 μl 3.25 mM
dTTP, 1.4 μl 1 mM Biotin-16-dUTP (ROCHE, Penzberg,
Germany) and 1.8 μl MMLV-RT (200 U/μl, Invitrogen)
was added to get a final volume of 30 μl. The reaction mix-
ture was incubated for 2 h at 37°C, and afterwards
stopped by adding of 1 μl 200 mM EDTA (final concentra-
tion ca. 7 mM). The sample was precipitated with 0.1 vol
4 M LiCl/2.5–3 vol ice cold absolute ethanol, washed with
ice cold 70% ethanol and resuspended in 10 mM EDTA.
Labelling with Klenow fragment
After First Strand cDNA synthesis with oligo-dT15-primer
(Promega) and MMLV-RT (Invitrogen) the resulting
cDNA was precipitated with LiCl/ice cold absolute etha-
nol, washed with ice cold 70% ethanol and dried. The pel-
let was resuspended in 68 μl deionisized water. This
mixture served as template for a labelling reaction with
Klenow-Fragment, exo-. We used the BioLabel DNA-
Labelling Kit (Fermentas) and followed the protocol pro-
vided by the manufacturer to generate a biotin labeled
hybridization sample. This DNA was purified by precipi-
tation (LiCl/Ethanol) for further applications.
Eberwine protocol
The First Strand cDNA was prepared with an oligo-dT T7-
primer (5'-AAA CGA CGG CCA GTG AAT TGT AAT ACG
ACT CAC TAT AGG CGC TTT TTT TTT TTT TTT TTT TTT
TTT-3') and Superscript II RT (200 U/μl, Invitrogen) in a
thermal cycler (10 minutes at 20°C, 60°C minutes at
37°C, final volume 10 μl). To generate the second strand
an ice cold mastermix of 52.75 μl water, 7.5 μl 10×Second
Strand buffer, 1.5 μl 10 mM dNTPs, 1 μl E. coli DNA-
Ligase (5 U/μl, Fermentas), 2 μl DNA polymerase I (10 U/
μl, Fermentas) and 0.25 μl RNase H (4.5 U/μl, Fermentas)
was added to the cooled first strand tubes (final volume
75 μl). The double stranded cDNA (ds-cDNA) was puri-
fied by extraction with one volume phenol (once) and
one volume of a chloroform/isoamyl alcohol mixture
(24:1, once) and precipitated with 8 M NH4-acetate/etha-
nol at room temperature, washed twice with ice cold 70%
ethanol and dried. The pellet was resuspended in 4 μl
water. For In Vitro Transcription we used the Ambion
Megascript kit (Ambion, USA). All components except the
enzyme were allowed to come to room temperature. 1 μl
of each component was added to the 4 μl ds-cDNA prep-
aration and incubated for 16 h at 37°C. The resulting anti-
sense RNA was purified with the RNeasy mini kit (Qiagen,
Hilden, Germany) according to the manufacturer's proto-
col.
Table 2: Relative expression level of selected genes (fluorescence and transmission values, respectively) versus expression level 
determined by quantitative RT-PCR (non stimulated cell line)
gene Affymetrix chip Array tube Quantitative RT-PCR
ST14 1000; 3000 1,6 6*10-3 ng
MMP1 6320,6 1,2 3,6*10-4 ng
TIMP3 619; 976; 1564,5 1,15 2,2*10-4 ng
CTSK 273,8 +) 0,43 8,13*10-6 ng
PAI-1 Not present 0,84 4,34*10-7 ng
+) this value is below the cut off of 300.BMC Genomics 2006, 7:144 http://www.biomedcentral.com/1471-2164/7/144
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SPA
Single primer amplification (SPA) and labelling with Kle-
now fragment exo- was performed according to the origi-
nal protocol published in [16].
Labelling in the course of linear amplification reactions
Double stranded cDNA generated according to the Eber-
wine protocol described above served as template for
labelling during the linear amplification reactions. For
overall amplification we used a primer with the sequence
of the T7-promoter (called SPA primer, analogue to the
SPA-protocol).
For specific amplification of selected targets we used
amounts of ds-cDNA-preparations representing original
amounts of 50–100 ng total RNA. An ice cold mixture of
water, 1.5 μl MgCl2 (50 mM), 5 μl 10×PCR buffer (Invit-
rogen), 1.5 μl 5 mM dNTPs (dATP, dCTP, dGTP), 0.5 μl
3.25 mM dTTP, 0.86 μl 1 mM Biotin-16-dUTP (ROCHE),
0.6  μl Taq polymerase (5 U/μl, Invitrogen) and 3 μl
primer mix (1 μM each) resulting in a final primer concen-
tration of 60 nM each was added to the template (final
volume 50 μl). The amplification was performed in a ther-
mal cycler according to the following protocol: 3 min
94°C, 40 cycles: 1 min 94°C, 1 min 62°C, 2 min 72°C,
cooling to 4°C. The reaction mixture was divided to get
material for duplicates and used for hybridization without
further purification steps.
Hybridization and detection
The array tube was conditioned by washing three times
with 500 μl distilled water and once with 500 μl hybridi-
zation buffer 1 (Clondiag, Jena) at 25°C for 5 minutes. All
steps were carried out using a horizontal shaker with tem-
perature regulation (550 rpm, Thermomixer compact,
Eppendorf, Germany). Biotinylated spike controls (0.05
μl each, equivalent to 6.7 × 10-6-1 × 10-5 nmol) were
added to the samples as external control for hybridiza-
tion, conjugation of enzyme and signal development due
to TMB precipitation.
The samples were denatured at 95°C for 10 min and
briefly centrifugated at 13000 rpm to collect the sample.
200 μl of pre-warmed hybridization buffer (50°C) was
added to each sample and the resulting mixture trans-
ferred into the array tube. Hybridization was allowed to
proceed on the shaker for 3 h at 50°C and 550 rpm.
The array tube was washed with 500 μl 2×SSC/0.01% Tri-
ton (5 min, 30°C), 2×SSC (5 min, 20°C) and 0.2×SSC (5
min, 20°C). After blocking with 100 μl of a blocking solu-
tion (2% milk powder, freshly prepared in 6×SSPE/
0.005% Triton, 15 min, 30°C) the array was incubated for
15 min at 30°C with 100 μl of a 1:10 000 dilution of HRP
Streptavidin (1 mg/ml, Clondiag, Jena) freshly prepared
in 6×SSPE/0.005% Triton. Following that the array was
washed twice with 500 μl 2×SSC/0.01 Triton (2 min,
30°C), twice with 500 μl 2×SSC and once with 0.2×SSC (5
min, 20°C).
The peroxidase pecipitation reaction (100 μl peroxidase
substrate, Clondiag, Jena) was monitored by the ATR01
array tube reader (Clondiag, Jena) at 25°C recording 60
images (one image per 10 sec). Data analysis was carried
out using IconoClust software Version 2.2 (Clondiag)
determining the signal intensity and the local background
value of each spot. The local background absorbance was
subtracted from the absorbance of the spots. Only the
average values of redundant spot hybridization signals
with amounts above 0.05 (mean – local background val-
ues) were considered as positive. Both spotted oligos of an
examined gene had to be "positive" to be considered as
expressed. If these conditions were met, the signal result-
ing from the hybridization with the oligo sequence situ-
ated closer at the 3'end of the RNA sequence was used for
further calculations.
Real time PCR (QRT-PCR) experiments
QRT- PCR experiments were carried out using a MyiQ™
Single colour QRT- PCR detection system (BIORAD, Her-
culas, CA). Reaction mixtures contained: 1 μl cDNA, 9.5
μl water, 2 μl primer mix (sense and antisense, 10 μM
each), and 12.5 μl iQ SYBR Green Supermix (BIORAD,
final volume 25 μl). A dilution series (10-2 - 10-6ng) of the
specific PCR product of interest was prepared to deter-
mine the standard curve (absolute quantification). Tem-
plate free controls served as a test of primer quality
(formation of dimers etc.). First of all the melting curve of
each target was measured to determine the optimal tem-
perature for real time analysis (e.g. ß-actin: 72°C, PAI-1:
83°C, matriptase: 89°C, TIMP3: 85°C). The samples were
amplified according to the following protocol: 3 min
95°C, 35 cycles: 20 sec 95°C, 40 sec 58°C, 1 min 72°C,
real time data registration for 8 sec at the specific temper-
ature determined before for each target. All samples were
measured in duplicates and the right formation of the
products was verified by agarose gel electrophoresis (1%
agarose, unknowns, standards and no template control,
product sizes: matriptase 470 bp, PAI-1 687 bp, TIMP3
445 bp). Real time data analysis was carried out using the
optical system software version 1.0 supplied with the
MyiQ™ real time instrument (BIORAD).
Stimulation experiments
Primary human fibroblasts were isolated from arthritic
patients according to the rules of the ethic commission of
the Friedrich Schiller University Jena. Cells were cultured
in DMEM/high glucose, 10% FCS, gentamycine 0.5 ml/
100 ml (in triplicate, 75 cm2 flasks) until 80% confluence
was reached. The medium was removed; the cells wereBMC Genomics 2006, 7:144 http://www.biomedcentral.com/1471-2164/7/144
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washed twice with FCS free medium and further cultured
in FCS free medium overnight. The medium was then
removed, and 4 ml of fresh FCS free medium was used for
stimulation experiments. The first sample served as con-
trol (FCS free medium without any cytokine. The second
sample was stimulated with 20 ng IL6/ml medium, the
third sample was stimulated with 2 ng TGFß/ml medium.
Stimulation was performed for 24 hours. Medium was
removed, cells were harvested and RNA was isolated with
TRIZOL® reagent as described above. RNA quality was
checked by non denaturing agarose gel electrophoresis
and used for preparation of double stranded cDNA
according to the first steps of the Eberwine protocol (see
above). Additionally, an established human fibroblast
line was also used for expression analysis.
Abbreviations
aRNA antisense RNA
DMEM Dulbeccos Minimum Essential Medium
ds-cDNA double stranded cDNA
DTT Dithiothreitol
EDTA ethylenediaminetetraacetic acid
FCS Fetal Calf Serum
HRP Horse Radish Peroxidase
IVT In Vitro Transcription
MMLV-RT Moloney Murine Leukemia Virus Reverse Tran-
scriptase
PCR Polymerase Chain Reaction
QRT-PCR Quantitative Real Time PCR
rpm rounds per minute
SPA Single Primer Amplification
SSC Sodium Saline Citrate
SSPE Sodium Saline Phosphate Ethylenediaminetetraace-
tic acid
TMB 3, 3', 5, 5'-Tetramethylbenzidin
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